HIMS products shown.
HIMS & HERS
Stocks Hims & Hjer Health Friday after the US Food and Medication Administration More than 23% broke down announced that semaglutide injection products have been resolved.
Semaglutide is an active ingredient in Novo NordiskWeight loss medicines at Blockbuster Wegovy and Diabetes Treatment O Sepic. These drugs are part of the drug class called GLP-1, and demand for treatments has exploded in recent years. As a result, digital health companies such as HIMS’s Hers prescribed complex semaglutide as an alternative to patients moving in volatile obstacles to supply and insurance obstacles.
Complex drugs are adapted to alternatives to medicines with brands intended to meet certain patients’ needs, and they can be produced when treatments with brand brands are lack. FDA does not examine The safety and effectiveness of complex products.
Hims & Hers started offering complex semaglutide patients In Mayand owns pharmacies that produce medication.
Complex drugs are usually much cheaper than their branded colleagues. HIMS & HERS sells complex semaglutide for less than $ 200, while Omempic and Wegovy Novo Nordisk cost about $ 1000 without insurance.
The FDA announced on Friday that it would start taking measures against compounds due to violation in the next 60 to 90 days, depending on the type of object, to “avoid unnecessary disorder of patient treatment”.
“Now that the FDA has found that the lack of semaglutide drugs has been resolved, we will continue to offer access to personalized treatments as the law is allowed to meet the needs of patients,” the executive director of Hims -a her Andrew Dudum Posted on X Friday. “We also closely monitor potential future shortcomings, as Novo Nordisk stated two weeks ago that he will continue to have” capacity limitations “and” the expected permanent periodic supply limitations and related notifications of the lack of drugs. “
The company’s weight loss offer was a huge hit with investors. The company’s shares climbed over 200% last year, and the shares have already increased more than 100% this year despite the move on Friday.
Even before adding complex GLP-1 to its portfolio, the company has announced in its 2023. Earnings in the fourth quarter Call that he expects his weight loss program to make more than $ 100 million in revenue by the end of 2025.
Despite the tumultuous regulatory landscape, Hims & Hers did not show signs of slowing down.
On Friday, the company announced He has acquired an American peptide object that “will further verticalize the long -term company’s ability to deliver personalized drugs.” HIMS & HERS will explore progress through metabolic optimization, recovery science, biological resistance, cognitive performance and preventative health through acquisition, The company said.
That move comes only a few days after Hers bought Trybe LabsHome testing plant based in New Jersey. Trybe Labs will allow him to do her Make blood at home and comprehensive processing testing.
HIMS & HERS did not disclose the terms of any job.
